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Abstract
Hepatitis B virus (HBV) infection remains a major health problem worldwide and a major 
risk factor for end-stage liver disease and hepatocellular carcinoma. Notable differences 
of chronic hepatitis B prevalence were observed in geographic area. In highly endemic 
areas, at least 50 % of HBV infections are most commonly acquired either perinatally or 
in early childhood, during the first 5 years of life. The prevalence of chronic HBV infec-
tion in pregnant women is expected to mirror those in the general populations of each 
geographic area. Chronic hepatitis B during pregnancy is associated with high risk of 
maternal complications and an increased risk of mother-to-child transmission (MTCT). 
Thus, chronic hepatitis B during pregnancy can now be considered an important con-
tributor to new HBV infections and to the global burden of disease. As a result, HBV 
infection during pregnancy requires management strategies for both the mother and the 
fetus/neonate, including prevention/elimination of MTCT and lessening the HBV effects 
on maternal and fetal health. This chapter will review current management strategies for 
hepatitis B in the pregnancy and the postpartum period, including special considerations 
on the effects of pregnancy on the course of HBV infection, MTCT, and antiviral therapy 
during the pregnancy.
Keywords: hepatitis B virus, pregnancy, mother-to-child transmission, disease burden, 
antiviral treatment, HBV vaccination, hepatitis B immune globulin (HBIG)
1. Introduction
Hepatitis B is caused by hepatitis B virus (HBV), a partially double-stranded DNA virus, 
member of the Hepadnaviridae family. The hepatitis B virion is a 42-nm particle composed 
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of a 27-nm nucleocapsid consisting of the hepatitis B core antigen (HBcAg) surrounded by 
an outer lipoprotein coat envelope containing the hepatitis B surface antigen (HBsAg) [1, 2].
To date, 10 HBV genotypes (A–J) have been defined based on intergroup divergence of above 
8 % in the complete nucleotide sequence and over 30 subgenotypes. The genotypes show 
heterogeneity in their global geographic distribution and have also been associated with dif-
ferent clinical features and different responses to antiviral therapy [3–6].
HBV infection remains a major health problem worldwide and a major risk factor for end-
stage liver disease and hepatocellular carcinoma. Two billion people worldwide have been 
infected with HBV, and more than 240 million people have chronic hepatitis B infection 
defined as HBsAg positive for more than 6 months. Despite the fact that in many countries 
HBV infections have declined substantially because of effective prevention strategies, more 
than 780,000 people die every year worldwide due to HBV complications, including cirrhosis 
and liver cancer [2].
HBV infection is transmitted by percutaneous and mucous membrane via blood or infected 
body fluids [7]. HBV mother-to-child transmission (MTCT), defined as HBsAg positivity at 
6–12 months of life in an infant born to an infected mother, has been recognized as a major 
mode of transmission and at the same time the most important phase for the chronic hepati-
tis B prevention. In Asia, up to 50 % of new cases of HBV infection are due to MTCT [8–10]. 
In Europe, MTCT is the most important and frequent transmission route of HVB infection, 
which accounted for 41.1 % of all cases, according to the results of the first enhanced surveil-
lance data collection of HVB infections across 30 countries of the European Union and the 
European Economic Area [11].
Infants born to HBsAg-positive mothers who do not become infected perinatally remain at 
risk of HBV infection during early childhood [12]. More than one third of patients with HBV 
acquired the infection during the perinatal period or in early childhood, even in low-endemic 
areas [13]. In highly endemic areas, at least 50 % of HBV infections are most commonly 
acquired either perinatally or in early childhood, during the first 5 years of life [2]. Moreover, 
the rate of chronicity is about 90 % for perinatally acquired HVB infection or during the first 
year of life, 30–50 % in infected children between ages 1 and 6 years, and 5–10 % in children 
over the age of 6 years and in adults [2, 14].
Thus, chronic hepatitis B during pregnancy is now an important contributor to the new HBV 
infections and to the global burden of disease.
2. Epidemiologic aspects of HBV infection in pregnant women
Notable differences of chronic hepatitis B prevalence were observed by geographic area, 
with the highest endemicity levels in the sub-Saharan Africa and East Asia (5–10 %) and 
low prevalence (<1 %) in the United States (USA), Canada, and Western Europe. High 
rates of prevalence have also been found in the southern regions of Eastern and Central 
Europe [2, 15].
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According to the technical report of the European Centre for Disease Prevention and Control 
(ECDC), based on literature review, the prevalence of HBsAg in the general population 
ranged from 0.1 to more than 7 % by country. Countries in the central or southern part of the 
Europe (EU) have a higher prevalence of HBV infection than countries in the northern or west-
ern part of the EU. Thus, Romania, Greece, and Turkey have a high HBV prevalence (>2 %); 
Italy has medium HBV prevalence (>1 and ≤2 %), while Belgium, France, Spain, Germany, 
the Netherlands, Slovakia, Sweden, Switzerland, and the United Kingdom have a low HBV 
prevalence (≤1 %). Among countries with available data, Turkey has the largest number of 
HBV-infected individuals (national and regional estimates ranged from 2.5 to 9.0 % in adults 
and 1.7 to 2.7 % in children only), followed by Romania (5.6 %) [16].
The prevalence of chronic HBV infection in pregnant women is expected to mirror those in 
the general populations of each geographic area. Thus, in higher endemicity areas, rates are 
proportionately higher [9].
In the United States, a country of low endemicity, estimated chronic HBV infection prev-
alence in pregnant women is 0.7–0.9 % [17]. In Europe, the chronic HBV infection preva-
lence in pregnant women is generally higher than in the general population (0.1–4.4 %) in 
countries where both estimates were available (e.g., Germany, Greece, Ireland, Italy, the 
Netherlands, and Slovakia), according to the ECDC study. This difference in prevalence can 
be attributed to the fact that migrant women, whom have a relatively high HBV infection 
prevalence, are better represented in pregnancy studies than in general population studies. 
Conversely, Spain reported in Catalonia in 2004 a lower prevalence of chronic hepatitis B in 
pregnant women than the prevalence in the general population in the same region in 2002 
(0.7 %), attributing these aspects to the higher vaccination rate [16]. In France, the prevalence 
of chronic HBV infection is about 1 % in pregnant women [18]. In Denmark, country where 
all pregnant women have been screened for HBV since November 2005, the overall preva-
lence of HBV infection among pregnant women has increased from 0.11 % in 1971 to 0.26 % 
in 2007. In the same period, the prevalence among pregnant native Danes decreased from 
0.11 to 0.01 % [19].
Available data suggest a wide variation in prevalence of chronic HBV infection among preg-
nant women globally. However, there are insufficient epidemiological data and limitations to 
estimate the epidemiology of HVB infection among pregnant women globally.
3. Serological markers of HBV infection
Measurement of several HBV antigens and/or antibodies plays an important role in diagnosis, 
assessment, and monitoring the disease progression and its response to treatment.
There are three clinical useful antigen-antibody groups used in the serological diagnosis of 
HVB:
1. Hepatitis B surface antigen and antibody: antigen (HBsAg) and antibody to HBsAg 
(anti-HBs)
Current Management Strategies in Hepatitis B During Pregnancy
http://dx.doi.org/10.5772/66068
191
2. Core antigen and antibodies: antigen (HBcAg does not appear in the blood) and antibody 
to HBcAg (anti-HBc), IgM antibody subclass of anti-HBc (IgM anti-HBc), and IgG antibody 
subclass of anti-HBc (IgG anti-HBc)
3. Hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe)
Additionally, the presence and concentration of circulating HBV DNA can also be tested 
[20–22].
HBsAg is the serological hallmark of both acute and chronic forms of HBV infection and the 
most commonly used diagnostic and blood screening marker for HBV infection. It usually 
appears in serum 1–10 weeks (average, 4 weeks) after acute exposure to the virus, and its per-
sistence for six months or more implies progression to chronic HBV infection. The presence of 
HBsAg indicates that the person is infected with HBV and is therefore potentially infectious. 
More than 95–99 % of adults with acute HBV infection will recover spontaneously, without 
antiviral therapy [23, 24].
In patients that recover completely from their HBV infection, HBsAg usually becomes unde-
tectable after four to six months, and its disappearance is followed several weeks later by 
the appearance of anti-HBs. Therefore, there is a gap ("window period") of several weeks to 
months between the disappearance of HBsAg and the appearance of anti-HBs, and during 
this period, the detectable marker of HBV infection is anti-HBc. The persistence of anti-HBs 
for a lifetime provides long-term immunity against HBV. Therefore, the presence of anti-HBs 
in serum attests to previous HBV exposure and acquired immunity. In some patients, anti-
HBs may not become detectable after disappearance of HBsAg. These patients do not appear 
to be susceptible to recurrent infection [20, 23, 24].
Total anti-HBc (IgM and IgG) appears before anti-HBs, and its presence in serum attests both 
past exposure and current HBV infection. Its presence during the “window period” makes it 
a reliable indicator of HBV infection, in the absence of other HBV markers [25].
IgM anti-HBc develops in acute HBV infection and may usually persist for four to six months 
if the infection resolves [20, 22]. Although it is considered a reliable serologic marker for acute 
infection, IgM anti-HBc can also become positive during a chronic hepatitis B flare in patients 
who have long-standing hepatitis B [26, 27].
A negative IgM anti-HBc in conjunction with a positive HBsAg likely suggests a chronic 
HBV infection. As a result, routine testing for IgM anti-HBc is not generally recommended to 
screen for acutely infected patients [28, 29].
IgG anti-HBc develops in the late acute phase of infection and generally remains detectable 
for lifetime [20]. IgG anti-HBc may be the only serologic marker remaining in patient serum 
who recover from acute HBV infection. The presence of IgG anti-HBc can indicate progression 
to chronic disease [22].
HBeAg is a viral soluble protein that develops in the serum of persons with acute or chronic 
HBV infection. HBeAg appears in serum early during acute HBV infection and usually dis-
appears about three weeks before HBsAg disappears. Persistence of HBeAg three or more 
months after the onset of illness indicates a carrier state and the risk of developing chronic 
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HVB. The HBeAg presence in the serum of HBV carriers and chronic hepatitis B patients indi-
cates greater infectivity and a high level of viral replication [20, 30].
The small-size soluble HBeAg can cross the placental barrier from the mother to the fetus 
especially through villous capillary endothelial cells. The maternal HBeAg-positive serologi-
cal status and high serum HBV DNA levels increase the risk of MTCT. By contrast, the absence 
of the HBeAg in serum is associated with lower levels of viral replication and with a signifi-
cantly lower risk of intrauterine HBV transmission. The infants born to HBeAg-positive moth-
ers have up to 90 % chance of acquiring perinatal HBV without prophylaxis [13, 14, 31, 32].
Anti-HBe appears in the resolution phase of the disease, when HBeAg disappears. Its pres-
ence correlates to a decreased infectivity. A seroconversion of HBeAg to anti-HBe marks a 
transition to the inactive carrier state in the majority of cases [20].
Spontaneous or treatment-induced HBeAg seroconversion is associated with lower rates of 
disease progression [33].
In addition to viral antigens and antibodies detected or measured, serum HBV DNA can also 
be measured both qualitatively and quantitatively (HBV viral load). HBV DNA is the most 
sensitive and specific marker of viral replication [29].
Serologic pattern of acute HBV infection is characterized by the transient presence of HBsAg 
(<6 months) and IgM anti-HBc. HBeAg and HBV DNA are also present during the initial 
phase of infection. The disappearance of HBV DNA, HBeAg to anti-HBe seroconversion, and 
loss of HBsAg or HBsAg to anti-HBs seroconversion designate recovery. The presence of IgG 
anti-HBc in the absence of HBsAg usually indicates a past HBV infection, while the presence 
of anti-HBs only reveals immunity to HBV infection after vaccination [20, 22, 25].
Three standard tests (HBsAg, anti-HBs, and anti-HBc) are usually indicated to determine if a 
person is currently infected with HBV, has recovered from HBV infection, or is susceptible to 
HBV infection [20].
Combinations of serologic HBV markers are used to identify different phases of HBV infec-
tion (Table 1).
Serological markers Results Interpretation
HBsAg Negative Never infected. Susceptible
Total anti-HBc Negative Vaccination should be recommended
Anti-HBsAg Negative
HBsAg Negative Recovered from past infection and 
immune
Total anti-HBc Positive
IgM anti-HBc Negative
Anti-HBsAg Positive
HBsAg Negative Immune due to hepatitis B vaccination
Total anti-HBc Negative
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4. Mechanisms and predictors for MTCT of HBV infection
Perinatal transmission of hepatitis B is highest in mothers with acute hepatitis, especially in 
HBe-positive mothers in the third trimester (50–80 %), lower in mothers with anti-HBe (25 %), 
and lowest in carriers (5 %) [34].
The World Health Organization (WHO) defines “perinatal” as the time period starting at 
22 completed weeks (154 days) gestation and ending seven complete days after birth [35]. 
However, the perinatal period is defined in various ways, and depending on the definition, it 
starts at the 20th–28th week of gestation and ends 1–4 weeks after birth [36]. The term MTCT 
is entitled and covers the transmission of all HBV infections from mother to her child during 
pregnancy (intrauterine transmission), childbirth, or after birth. As a result, there are three 
main possible routes for MTCT of HBV infection: transplacental transmission of HBV, trans-
mission during delivery, and postnatal transmission during child care and breastfeeding [37].
Intrauterine transmission of HBV is considered the most important cause for the failure of 
passive-active immunoprophylaxis in preventing MTCT, although it is presumed to cause a 
minority of HBV infections [38]. The main risk factors for intrauterine HBV infection are mater-
nal serum HBeAg positivity, high HBV DNA level, history of threatened preterm labor, and 
HBV presence in the villous capillary endothelial cells of the placenta. One of the proposed 
mechanisms involved in the HBV intrauterine transmission is the transplacental leakage of 
Table 1. Most common serological profiles of HBV infection [20, 22, 28].
Serological markers Results Interpretation
Anti-HBsAg Positive
HBsAg Positive Acute HBV infection
Total anti-HBc Positive
IgM anti-HBc Positive
Anti-HBsAg Negative
HBsAg Positive Chronic HBV infection
Total anti-HBc Positive
IgM anti-HBc Negative
Anti-HBsAg Negative
HBsAg Negative Interpretation of isolated detection of 
anti-HBc
Total anti-HBc Positive Resolved infection
Anti-HBsAg Negative Window period of acute HBV (anti-
HBc-predominantly IgM)
False-positive test results
“Low level” chronic infection
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HBeAg-positive maternal blood induced by uterine contractions during pregnancy and by 
the disruption of placental barriers. In addition, HBeAg can pass through the placenta via the 
“cellular route.” Although the risk of fetal hepatitis B infection through amniocentesis is con-
sidered to be low, the maternal HBeAg status would be valuable in the counseling regarding 
risks associated with amniocentesis. Another possible route of HBV intrauterine transmission 
could be via germ cells, maternally or paternally dependent [14, 37, 39].
HBV transmission during delivery is recognized as the most important route of MTCT in 
endemic areas for HBV infection, as a result of exposure to maternal cervical secretions and 
maternal blood that contain HBV. There is no consensus regarding the effect of delivery mode 
on MTCT (vaginal delivery vs. cesarean section). While some studies suggest that cesarean 
section might reduce the risk of MTCT, other studies assert that the mode of delivery does not 
influence the rate of HBV transmission as long as all infants received both hepatitis B vaccine 
and hepatitis B immune globulin (HBIG) at birth [37].
There is little evidence that cesarean delivery prevents HBV transmission, and current guide-
lines do not recommend cesarean section to decrease the risk of MTCT. As for elective cesar-
ean section (ECS), there are studies that show alike an absolute risk reduction of MTCT of 
HBV compared with immunoprophylaxis alone and studies that report no benefit to ECS. 
According to recent clinical guidelines of American College of Gastroenterology (ACG) con-
cerning liver disease and pregnancy, validation studies are needed to determine the rela-
tive safety and efficacy of ECS and immunoprophylaxis versus immunoprophylaxis alone in 
reducing MTCT of HVB [40].
Although markers of HBV are detectable in breast milk from HBsAg-positive women, there is 
no evidence that breastfeeding is a risk factor for HBV infection if the infant received hepatitis 
B vaccine and HBIG. According to the WHO and the American Academy of Pediatrics recom-
mendations, in infants who receive full immunoprophylaxis, breastfeeding in HBs-positive 
mothers is not a contraindication [9, 41, 42].
5. Clinical and laboratory features of HBV infection in pregnancy
The clinical manifestations of HBV infection may be variable in both acute and chronic dis-
eases. In acute HBV infection, clinical manifestations usually range from anicteric hepatitis to 
icteric hepatitis, while in the chronic phase, manifestations range from an asymptomatic car-
rier state to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Fulminant hepatic fail-
ure, most probably due to massive immune-mediated lysis of infected hepatocytes, is unusual 
but can occur in some cases. Extrahepatic manifestations may be present in both acute and 
chronic infections [25, 40, 42].
Testing for HBsAg should be performed in all women at the first prenatal visit, even if they have 
been previously vaccinated or tested, and repeated later in pregnancy if appropriate [25, 43].
The first step in assessing a woman presenting at any stage of pregnancy with acute or chronic 
HBV infection should be the same as with any nonpregnant patient: complete history, physical 
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exam, standard serological workup, laboratory test which should include assessment of liver 
disease activity and function, markers of HBV replication, and tests for coinfection with hepa-
titis C virus [8, 16, 40, 43, 44].
The clinical spectrum of acute HBV infection in pregnant women usually is not different from 
that of nonpregnant women; however, the risk of preterm delivery and low birth weight is 
higher than in the general population [9, 14, 42]. It seems that acute HBV infection does not 
increase mortality or have teratogenic effects [9].
Common symptoms of acute HBV infection in pregnant women are indistinguishable from 
those of nonpregnant, including upper quadrant discomfort, fatigue, nausea, vomiting, 
Phase ALT HBV DNA HBeAg Notes
“Immune tolerant” Normal Elevated Positive Perinatal or early 
childhood-acquired 
HBV infection
Patients are highly 
contagious Low 
spontaneous HBeAg 
loss Minimal liver 
inflammation and 
fibrosis
HBeAg-positive 
immune-active phase 
“Immune active”
Elevated Elevated Positive Moderate-to-severe 
liver inflammation or 
fibrosis HBeAg to anti-
HBe seroconversion 
possible, leading to 
“immune-control” 
phase
Inactive chronic 
hepatitis “Immune 
control”
Normal Low or undetectable Negative Low risk for cirrhosis 
Minimal liver 
necroinflammation, 
variable fibrosis
HBeAg-negative 
chronic hepatitis 
“Immune escape 
mutant”
Elevated persistent or 
intermittently
Moderate to elevated Negative Generally in older 
persons Liver 
necroinflammation 
Risk for fibrosis or 
cirrhosis
“Reactivation” or 
“acute-on-chronic 
hepatitis” or HBeAg-
negative immune 
reactivation phase
Elevated Elevated Negative Spontaneously or 
precipitated by 
immunosuppressive 
therapy, 
transplantation, 
antiviral resistance, 
HIV infection, 
withdrawal of antiviral 
therapy Moderate-
to-severe liver 
necroinflammation and 
fibrosis
Table 2. Phases of chronic hepatitis B [44–46].
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diarrhea, headaches, myalgia, anorexia, low-grade fever, and jaundice. The icteric phase of 
acute viral hepatitis usually begins within 10 days of the initial symptoms and disappears 
about 4–12 weeks afterwards. Diagnosis is based on the detection of HBsAg and the pres-
ence of IgM anti-HBc. Recovery is accompanied by HBsAg clearance with seroconversion to 
anti-HBs, usually within 3 months. Concentrations of alanine and aspartate aminotransfer-
ase (ALT and AST) levels usually increase, with ALT typically higher than AST. In patients 
who recover, normalization of serum aminotransferases usually occurs within one to four 
months [20, 25, 42, 45].
Acute exacerbation or flare of hepatitis in chronic HBV infections can be present during 
pregnancy, and it may be difficult to differentiate from acute HBV infection. HBV testing 
with HBsAg and IgM anti-HBc is recommended in pregnant women presenting with acute 
hepatitis [40].
Most chronic HBV infections are asymptomatic and pregnancy is well tolerated. Some 
patients may complain of fatigue, anorexia, and nonspecific malaise. Significant symp-
toms will develop only if the liver disease progresses. Cirrhosis, condition usually associ-
ated with amenorrhea and infertility, is relatively uncommon in the younger age group of 
pregnant women, and severe cases are fortunately rare [9, 42, 45]. The chronic hepatitis B 
is usually mild in pregnant women but may flare at the end of pregnancy or shortly after 
delivery [9].
The natural history of chronic HBV infection consists of several phases of variable duration, 
which are not necessarily sequential (Table 2) [44–46]. Pregnancy is a hormone-induced 
immune-tolerant state, and there is limited understanding of the natural history of chronic 
HBV infection during pregnancy [47]. Increased levels of adrenal corticosteroids and estro-
gen hormones during pregnancy may be responsible for an increase in HBV viral load and a 
decrease in ALT levels. A postpartum decline in HBV DNA level, associated with increased 
ALT levels and active hepatitis, requires close monitoring of the mother [9, 42].
6. Current management strategies for chronic hepatitis B in pregnancy
HBV infection during pregnancy requires management strategies for both mother and fetus/
neonate, including prevention/elimination of MTCT and lessening the HBV effects on mater-
nal and fetal health [48, 49].
Current management strategies for hepatitis B during pregnancy include antenatal maternal 
screening for HBV infection, initial assessment of mother with HBV infection (severity of liver 
disease, level of viral replication, presence of comorbidities), prophylactic HBV vaccination 
and HBIG administration to all infants born to HBV-infected mothers as soon as possible 
after birth, the use of antiviral medications for pregnant women with chronic hepatitis B, safe 
delivery practices, and strengthened maternal and child health services [8, 40, 45, 50].
Few countries have national hepatitis strategies, plans, and budgets, and as a consequence, 
the WHO recently published a 5-year global health sector strategy on viral hepatitis. This 
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includes testing algorithms, strategies for hepatitis B, diagnosis and management of acute 
hepatitis B, as well as management of advanced liver disease [8, 45].
Antenatal screening for HBV infection in all pregnant women is a well-established, evidence-
based standard of practice to prevent MTCT. Therefore, the first step is to identify all HBsAg-
positive pregnant women in the first trimester by universal screening [45].
All pregnant women who are HBsAg positive should be assessed the same way as any non-
pregnant individual: a complete history with special emphasis on risk factors for coinfection, 
physical exam and laboratory tests for assessment of liver disease activity and function, mark-
ers of HBV replication, and tests for coinfection (hepatitis C virus, hepatitis delta virus, or 
human immunodeficiency virus in those at risk) [24, 44, 48, 50].
Assessment of the severity of liver disease should include measurement of ALT, AST, alkaline 
phosphatase (ALP), gamma-glutamyl transpeptidase, total bilirubin, full blood count, serum 
albumin and globulins, prothrombin time, and an ultrasound examination. Assessment of 
the level of viral replication in chronic hepatitis B using quantification of serum HBV DNA 
and HBeAg and anti-HBe is an important step in determining the risk of MTCT and therefore 
in guiding antiviral therapy decisions and the need for surveillance [24, 44, 48, 50]. Elevated 
serum ALT and HBV DNA levels are strongly predictive of risk of liver complications [44].
According to the WHO Strategic Advisory Group of Experts, the currently recommended 
practice to reduce perinatal MTCT of HBV relies on the administration of HBV vaccine and, in 
some countries, concurrent administration of HBIG. The infants of all HBsAg-positive women 
should receive immunoprophylaxis with HBV vaccination ± HBIG. Hepatitis B vaccine and 
HBIG should be administered at different injection sites [45].
The timing of administration of the first dose of hepatitis B vaccine to infants in relation to 
birth is the most important factor in determining the efficacy of vaccination [41, 51]. As a 
result, the recommended timing of administration of the first dose of hepatitis B vaccine in 
newborns has evolved in the last decades, in order to optimize prevention of MTCT hepatitis 
B infections. The WHO recommends that all infants receive the hepatitis B vaccine as soon as 
possible after birth, within 24 h of the birth [2].
Passive immunization against hepatitis B with HBIG in conjunction with HBV vaccination 
may be of additional benefit for newborn whose mothers are HBsAg positive, particularly 
if they are also HBeAg positive [45]. According to the Centers for Disease Control, all pre-
term infants born to HBsAg-positive mothers and mothers with unknown HBsAg status must 
receive HBIG and hepatitis B vaccine within 12 h of birth [52].
Unfortunately, despite postnatal active-passive immunization of the newborns, MTCT of 
HBV still occurs, especially if the mother has very a high maternal concentration of HBV 
DNA, typically observed in HBeAg-positive women [45].
There are emerging data based on open-label nonrandomized studies which suggest that 
short-term maternal antiviral therapy used in pregnant women with stable liver disease dur-
ing the third trimester may reduce the risk of MTCT occurring during the perinatal period, by 
lowering maternal viral load prior to delivery [24, 47].
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Current guidelines of the American Association for the Study of Liver Diseases (AASLD), 
ACG, European Association for the Study of the Liver (EASL), and Asian Pacific Association 
for the Study of the Liver (APASL) suggest or recommend antiviral therapy to reduce the 
risk of perinatal transmission of hepatitis B in HBsAg-positive pregnant women with a HBV 
DNA above 200,000 IU/mL [24, 44, 48, 50]. As for the WHO current position, the Guidelines 
Development Group did not make a formal recommendation on the use of antiviral therapy 
to prevent MTCT, due to the fact that key trials are still ongoing and there is a lack of consen-
sus regarding the programmatic implications of a policy of more widespread antiviral use in 
pregnancy [45].
There are only three therapeutic antiviral agents studied and used for the treatment of 
chronic hepatitis B in pregnant women: lamivudine, telbivudine (nucleoside analogues 
(NAs)), and tenofovir disoproxil fumarate (nucleotide analogue). According to the US Food 
and Drug Administration classification of oral antiviral, based on the risk of teratogenic-
ity in preclinical evaluation, only two drugs from the nucleoside/nucleotide analogues 
(NAs) class—tenofovir and telbivudine—are classified in risk category B (no risk in ani-
mal studies, but unknown in humans), while lamivudine, entecavir, and adefovir dipivoxil 
are classified as category C drugs (teratogenic in animals, but unknown in humans) [24, 
44]. Additionally, tenofovir received category B classification based on data collected from 
human exposure [53].
Lamivudine, the first and the most studied NAs in pregnant women with chronic hepatitis B, 
is not considered an optimal choice for prevention of MTCT due to its poor antiviral activity 
and low barrier to resistance. Its administration, even for short periods, is associated with the 
selection of resistant mutants. Lamivudine reaches higher concentrations in amniotic fluid 
than in serum and has been found to be excreted in breast milk [49, 54, 55].
The results of small human pregnancy trials show that telbivudine reduces MTCT in highly 
viremic pregnant women and its use appears to be safe in late pregnancy [47].
Tenofovir is considered a preferred choice in pregnant women with chronic hepatitis B, due 
to its antiviral potency, the available safety data of use during pregnancy, and its better resis-
tance profile [44, 45].
As for other antiviral drugs, the safety of entecavir in pregnancy is not known, and interferon 
(IFN) therapy is contraindicated during pregnancy [44, 45].
Antiviral therapy was started at 28–32 weeks of gestation in most studies, and therefore NAs 
starting from 28 to 32 weeks of gestation are recommended [24, 45]. A careful examination to 
exclude maternal systemic disorder and fetal anomalies is required prior to the administra-
tion of NAs [44, 50]. For pregnant women with immune-active chronic hepatitis B, monitor-
ing therapeutic response to NAs, both serological and virological, as well as for potential 
side effects, should be based on recommendations for nonpregnant women [24, 44, 45]. 
Tenofovir therapy requires monitoring serum creatinine and serum phosphate levels every 
three months, due to potential nephrotoxicity. The risks of maternal liver disease, fetal devel-
opment, HBV MTCT, and long-term plan for treatment should be discussed with pregnant 
women [24, 50].
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Although there are no studies on the duration of NA therapy (cessation at delivery vs. after 
delivery), cessation of NA therapy (at delivery or 4–12 weeks after delivery) is recommended 
in females without ALT flares [24, 44, 45]. According to EASL guidelines, if NA therapy is given 
only for prevention of MTCT, it may be discontinued within the first 3 months after delivery 
[50]. If the anti-HBV therapy is discontinued during pregnancy or early after delivery, women 
need to be closely monitored for the risk of hepatic flares, especially after delivery [44, 50].
In certain situations, such as ALT flares detected during the treatment period, continuation 
of antiviral treatment after delivery is needed. As a result, this raises the issue of safety of 
NA therapy during breastfeeding. Due to limited data on the effect of these medications on 
infants, the safety of NA therapy during breastfeeding is considered uncertain [24, 50].
The safety of lamivudine and tenofovir during breastfeeding in HBV infection has not been 
well studied. Additionally, tenofovir and lamivudine concentrations in breast milk have been 
reported. However, due to its poor oral bioavailability, the breastfeeding infants are exposed 
to only small tenofovir concentrations [50].
According to drug labels, tenofovir disoproxil fumarate and lamivudine should not be used 
during breastfeeding. Breastfeeding is discouraged during maternal NA treatment according 
to APASL current guidelines, but in the case of ALT flares, continuation of antiviral may be 
indicated, depending on the liver disease status of mother [24]. A recent review of available 
data concluded that tenofovir and lamivudine should not be contraindicated during breast-
feeding. However, there are insufficient data based on long-term studies to establish the 
safety of infant exposure to different antiviral therapies during breastfeeding [56].
7. Conclusions
Despite advancements in the prevention, diagnosis, and treatment of HBV infection, it remains 
a serious global health issue and one of major risk factors for end-stage liver disease and 
hepatocellular carcinoma. Given that chronic hepatitis B in pregnant women is an important 
contributor worldwide to the new HBV infections, most effective and sustainable measures 
are required for prevention of MTCT. Universal screening of pregnant women for HBsAg and 
passive and active immunoprophylaxis are important tools in MTCT of HBV. The causes of 
immunoprophylaxis failure in some infants are not yet not fully understood, and, therefore, 
studies are needed in order to clarify this issue. Longitudinal cohort studies are also required 
to determine the safety of infant exposure to different NA therapies during breastfeeding.
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